Vivos Therapeutics Presents Study Results at SLEEP 2022 Meeting


A study from Vivos Therapeutics demonstrated that airway repositioning and/or expansion can help patients with obstructive sleep apnea.

Vivos Therapeutics Presents Study Results at SLEEP 2022 Meeting

Vivos Therapeutics Presents Study Results at SLEEP 2022 Meeting

Obstructive sleep apnea (OSA) technology company Vivos Therapeutics has announced positive results from a retrospective study with Vivos patients at this year’s SLEEP 2022. SLEEP, is the annual meeting of the Associated Professional Sleep Societies, held by the American Academy of Sleep Medicine and Sleep Research Society.

The study results were presented by Dr Seth Heckman in a presentation titled “Non-Surgical Maxillary Expansion Using a Novel Oral Appliance System.” The study, which looked at 786 patients that used a Vivos’ treatment via oral appliances, demonstrated that use of these devices may result in maxillary and airway expansion. Participants experienced a 4.5% increase in transpalatal widths and an 11.1& increase in airway volumes.

This therapy is called Complete Airway Repositioning and/or Expansion (CARE). Vivos treatment allows for a 1–2-year treatment length, which sets it apart from traditional, lifetime CPAP therapies. The study reinforces this idea with its pre- and post-treatment measurements taken without the appliance in the mouth. 139 patients showed a decrease in their Apnea Hypopnea Index (AHI) by over 50% in 61.6% of the patients and decreased overall OSA severity in 56.8% of the patients.

“This largest dataset to-date reinforces what Vivos dentists have been saying for years—airway volume and maxillary expansion can be seen following a finite course of Vivos oral appliance therapy,” Dr Heckman said in a press release from Vivos. “Our data highlights that patients with OSA may now have access to a long-sought 4th treatment modality: positive airway pressure, mandibular advancement, surgery, and now CARE.”

CARE is designed to be less invasive while being equally effective, according to Vivos Chairman and CEO Kirk Huntsman.

“Sleep apnea contributes to multiple physical and mental health issues that most patients don’t even realize which may include high blood pressure/hypertension, heart failure, stroke, coronary artery disease, depression/anxiety, and many other life-threatening illnesses,” Huntsman said in the press release. “With innovative modern technologies like CARE, highly invasive, lifetime inventions like CPAP machines and surgeries may no longer be the only answer for patients in need.

This presentation was given on June 6th, 2022.

Related Videos
Greater New York Dental Meeting 2023 – Interview with Anthony P Urbanek, DDS, MS, MD
Product Bites – December 8, 2023
Product Bites December 1, 2023
Product Bites - November 24, 2023
Product Bites – November 17, 2023
Discussing Dental Artificial Intelligence with Stephen DiBenedotto, DDS, FAGD
Product Bites – November 10, 2023
Product Bites – October 27, 2023
 Product Bites – October 20, 2023
Product Bites – October 13, 2023
Related Content
© 2023 MJH Life Sciences

All rights reserved.